PAVmed strengthened its capital structure and relaunched its medical device portfolio under new leadership
Processed 3,664 EsoGuard ® tests and recognized 4Q25 revenue of $1.5 million
Conference Call and Webcast at 8:30 AM ET
Series D Preferred Stock offering yielded $30 million of gross proceeds and includes warrants exercisable for up to an additional $30 million upon publication of a positive draft EsoGuard Medicare local...
NEW YORK , Jan. 21, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics...
NEW YORK , Dec. 30, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical...
Report includes nearly 12,000 patients who underwent Lucid's EsoGuard ® Esophageal DNA Test on samples collected using its EsoCheck ® Esophageal Cell Collection Device
Recognized as the leading company in its size category in program honoring the top workplaces across the diagnostics and precision-medicine sectors
Veris Health launched commercial phase of strategic partnership and relaunched development of implantable physiological monitor
Processed 2,841 EsoGuard ® tests and recognized 3Q25 revenue of $1.2 million, ending quarter with over $47 million in proforma cash and extending runway through 2026 and well past upcoming reimbursement...